1
|
Zhang YL, Yang R, Xia LY, Man RJ, Chu YC, Jiang AQ, Wang ZC, Zhu HL. Synthesis, anticancer activity and molecular docking studies on 1,2-diarylbenzimidazole analogues as anti-tubulin agents. Bioorg Chem 2019; 92:103219. [DOI: 10.1016/j.bioorg.2019.103219] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2019] [Revised: 07/11/2019] [Accepted: 08/24/2019] [Indexed: 01/08/2023]
|
2
|
Šiviková K, Holečková B, Schwarzbacherová V, Galdíková M, Dianovský J. Potential chromosome damage, cell-cycle kinetics/and apoptosis induced by epoxiconazole in bovine peripheral lymphocytes in vitro. CHEMOSPHERE 2018; 193:82-88. [PMID: 29127838 DOI: 10.1016/j.chemosphere.2017.11.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 10/23/2017] [Accepted: 11/03/2017] [Indexed: 06/07/2023]
Abstract
The epoxiconazole was tested in vitro for its potential on induction of chromosome damage and/or cell cycle kinetics in cultured bovine peripheral lymphocytes. Cytogenetic endpoints such as: Chromosome Aberrations (CA); Sister Chromatid Exchanges (SCE); Micronuclei (MN); Mitotic Index (MI); Proliferation Index (PI); and Cytokinesis Block Proliferation Index (CBPI) were investigated for 24 h and 48 h of incubation. The cultured lymphocytes were exposed to the epoxiconazole at concentrations of 2.5, 5, 10, 25, 50 and 100 μg mL-1. From our results is evident that treatment of bovine peripheral lymphocytes with the epoxiconazole was not related to DNA damage; no genotoxic effect and/or clastogenic/aneugenic effects were recorded. However, epoxiconazole has ability to significantly affect cell cycle kinetics/and induce apoptosis. A decrease of proliferation in the MI, CBPI and identically in the PI were observed; hence, cytostatic/cytotoxic effects of epoxiconazole have been recorded. The prolonged time of exposure at the highest concentration caused an inhibition of the replication. Electrophoretic analysis confirmed the epoxiconazole potential to induce ladder-like patterns of DNA fragments that are a hallmark of apoptosis.
Collapse
Affiliation(s)
- Katarína Šiviková
- Institute of Genetics, University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic.
| | - Beáta Holečková
- Institute of Genetics, University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic
| | - Viera Schwarzbacherová
- Institute of Genetics, University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic
| | - Martina Galdíková
- Institute of Genetics, University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic
| | - Ján Dianovský
- Institute of Genetics, University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic
| |
Collapse
|
3
|
Zuo D, Pang L, Shen J, Guan Q, Bai Z, Zhang H, Li Y, Lu G, Zhang W, Wu Y. 5-(Furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3-one oxime (6f), a new synthetic compound, causes human fibrosarcoma HT-1080 cell apoptosis by disrupting tubulin polymerisation and inducing G2/M arrest. Int J Oncol 2017; 50:2069-2078. [PMID: 28440465 DOI: 10.3892/ijo.2017.3963] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 03/13/2017] [Indexed: 11/06/2022] Open
Abstract
In the current study, we synthesized a series of new compounds targeting tubulin and tested their anti-proliferative activities. Among these new synthetic com-pounds, 5-(furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3-one oxime (6f) exhibited significant anti-proliferative activity against different human cancer cell lines including human gastric adenocarcinoma SGC-7901, human non-small cell lung cancer A549, and human fibrosarcoma HT-1080. As a result, 6f was selected to further test the sensitivity to different cancer cell lines including human cervical cancer cell line HeLa, human breast cancer cell line MCF-7, non-small cell lung cancer cell line A549, human liver carcinoma cell line HepG-2, human oral squamous cell carcinoma cell lines KB, SGC-7901 and HT-1080. Among these cell lines, HT-1080 and HeLa are the most sensitive. Therefore, HT-1080 was selected to further explore the properties of anti-proliferative activity and the underlying mechanisms. Our data proved that 6f exhibited strong anti-proliferative effects against HT-1080 cells in a time- and dose-dependent manner. We showed that the growth inhibitory effect of 6f in HT-1080 cells was related with microtubule depolymerisation. Molecular docking studies revealed that 6f interacted and bound efficiently with the colchicine-binding site of tubulin. In addition, 6f treatment induced G2/M cell cycle arrest dose-dependently and subsequently induced cell apoptosis. Western blot study indicated that upregulation of cyclin B1 and p-cdc2 was related with G2/M arrest. 6f-induced cell apoptosis was associated with both mitochondrial and death receptor pathway. In conclusion, our data showed that 6f, among the newly synthetic compounds, exhibited highest anti-proliferative activity by disrupting the microtubule polymerisation, causing G2/M arrest and subsequently inducing cell apoptosis in HT-1080 cells. Hence, 6f is a promising microtubule depolymerising agent for the treatment of various cancers especially human fibrosarcoma.
Collapse
Affiliation(s)
- Daiying Zuo
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Lili Pang
- Department of Clinical Pharmacy, The Sixth People's Hospital of Chengdu, Chengdu, Sichuan 610051, P.R. China
| | - Jiwei Shen
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Qi Guan
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Zhaoshi Bai
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Huijuan Zhang
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Yao Li
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Guodong Lu
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Weige Zhang
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| | - Yingliang Wu
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
| |
Collapse
|
4
|
Malebari AM, Greene LM, Nathwani SM, Fayne D, O'Boyle NM, Wang S, Twamley B, Zisterer DM, Meegan MJ. β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells. Eur J Med Chem 2017; 130:261-285. [PMID: 28254699 DOI: 10.1016/j.ejmech.2017.02.049] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Revised: 02/18/2017] [Accepted: 02/20/2017] [Indexed: 11/17/2022]
Abstract
Glucuronidation by uridine 5-diphosphoglucuronosyl transferase enzymes (UGTs) is a cause of intrinsic drug resistance in cancer cells. Glucuronidation of combretastatin A-4 (CA-4) was previously identified as a mechanism of resistance in hepatocellular cancer cells. Herein, we propose chemical manipulation of β-lactam bridged analogues of Combretastatin A-4 as a novel means of overcoming drug resistance associated with glucuronidation due to the expression of UGTs in the CA-4 resistant human colon cancer HT-29 cells. The alkene bridge of CA-4 is replaced with a β-lactam ring to circumvent potential isomerisation while the potential sites of glucuronate conjugation are deleted in the novel 3-substituted-1,4-diaryl-2-azetidinone analogues of CA-4. We hypothesise that glucuronidation of CA-4 is the mechanism of drug resistance in HT-29 cells. Ring B thioether containing 2-azetidinone analogues of CA-4 such as 4-(4-(methylthio)phenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (27) and 3-hydroxy-4-(4-(methylthio)phenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (45) were identified as the most potent inhibitors of tumour cell growth, independent of UGT status, displaying antiproliferative activity in the low nanomolar range. These compounds also disrupted the microtubular structure in MCF-7 and HT-29 cells, and caused G2/M arrest and apoptosis. Taken together, these findings highlight the potential of chemical manipulation as a means of overcoming glucuronidation attributed drug resistance in CA-4 resistant human colon cancer HT-29 cells, allowing the development of therapeutically superior analogues.
Collapse
Affiliation(s)
- Azizah M Malebari
- School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College Dublin, Dublin 2, Ireland.
| | - Lisa M Greene
- School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College Dublin, Dublin 2, Ireland
| | - Seema M Nathwani
- School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College Dublin, Dublin 2, Ireland
| | - Darren Fayne
- Molecular Design Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland
| | - Niamh M O'Boyle
- School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College Dublin, Dublin 2, Ireland
| | - Shu Wang
- School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College Dublin, Dublin 2, Ireland
| | - Brendan Twamley
- School of Chemistry, Trinity College Dublin, Dublin 2, Ireland
| | - Daniela M Zisterer
- School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College Dublin, Dublin 2, Ireland
| | - Mary J Meegan
- School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Trinity College Dublin, Dublin 2, Ireland
| |
Collapse
|
5
|
2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol (SQ0814061), a novel microtubule inhibitor, evokes G2/M cell cycle arrest and apoptosis in human breast cancer cells. Biomed Pharmacother 2016; 78:308-321. [DOI: 10.1016/j.biopha.2016.01.040] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2015] [Accepted: 01/26/2016] [Indexed: 11/16/2022] Open
|
6
|
Carvalho PC, Santos EA, Schneider BUC, Matuo R, Pesarini JR, Cunha-Laura AL, Monreal ACD, Lima DP, Antoniolli ACMB, Oliveira RJ. Diaryl sulfide analogs of combretastatin A-4: Toxicogenetic, immunomodulatory and apoptotic evaluations and prospects for use as a new chemotherapeutic drug. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2015; 40:715-721. [PMID: 26410090 DOI: 10.1016/j.etap.2015.08.028] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 08/23/2015] [Accepted: 08/30/2015] [Indexed: 06/05/2023]
Abstract
Combretastatin A-4 exhibits efficient anti-cancer potential in human tumors, including multidrug-resistant tumors. We evaluated the mutagenic, apoptotic and immunomodulatory potential of two diaryl sulfide analogs of combretastatin A-4, 1,2,3-trimethoxy-5-([4-methoxy-3-nitrophenyl]thio)benzene (analog 1) and 1,2,3-trimethoxy-5-([3-amino-4-methoxyphenyl]thio)benzene (analog 2), as well as their association with the anti-tumor agent cyclophosphamide, in Swiss mice. Such evaluation was achieved using the comet assay, peripheral blood micronucleus test, splenic phagocytosis assay, and apoptosis assay. Both analogs were found to be genotoxic, mutagenic and to induce apoptosis. They also increased splenic phagocytosis, although this increase was more pronounced for analog 2. When combined with cyclophosphamide, analog 1 enhanced the mutagenic and apoptotic effects of this anti-tumor agent. In contrast, analog 2 did not enhance the effects of cyclophosphamide and prevented apoptosis at lower doses. These data suggest that analog 1 could be an adjuvant chemotherapeutic agent and possibly improve the anti-neoplastic effect of cyclophosphamide. Additionally, this compound could be a candidate chemotherapeutic agent and/or an adjuvant for use in combined anti-cancer therapy.
Collapse
Affiliation(s)
- Pamela Castilho Carvalho
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Edson Anjos Santos
- Biochemistry Laboratory, Center for Biological and Health Sciences, Federal University of Mato Grosso do Sul (Universidade Federal do Mato Grosso do Sul - UFMS), Campo Grande, Mato Grosso do Sul, Brazil
| | - Beatriz Ursinos Catelán Schneider
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Renata Matuo
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - João Renato Pesarini
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Andréa Luiza Cunha-Laura
- Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Antônio Carlos Duenhas Monreal
- Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Dênis Pires Lima
- Graduate Program in Chemistry, Institute of Chemistry (Instituto de Química - IQ), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Andréia Conceição Milan Brochado Antoniolli
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Rodrigo Juliano Oliveira
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil; Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil.
| |
Collapse
|